Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 7/15/21 → 12/31/24 |
Funding
- Novartis (domestic): $86,364.00
An Open Label, Multi-Center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
- Munker, Reinhold (PI)